MonumenTAL-1研究中talquetamab治疗复发/难治性多发性骨髓瘤的感染特征与体液免疫参数
基于1/2期MonumenTAL-1研究,报告talquetamab治疗复发/难治性多发性骨髓瘤(RRMM)的感染特征。339例患者接受皮下talquetamab 0.4 mg/kg每周或0.8 mg/kg隔周给药。感染发生率分别为58.7%、66.2%和72.5%,3/4级感染率相对较低,体液免疫得以保留。
要点
- 每周组、隔周组和既往T细胞重定向治疗组的感染发生率分别为58.7%、66.2%和72.5%。
- 3/4级感染发生率分别为21.7%、15.9%和27.5%,多发生于第1/2周期。
- 中性粒细胞在第2周期恢复,IgG在第3周期后恢复并持续升高至第17周期。
核心结论
- talquetamab治疗RRMM患者3/4级感染率相对较低且体液免疫得以保留,是重要且可能免疫抑制作用较弱的新型治疗选择。
研究设计与样本
- 基于1/2期MonumenTAL-1研究,纳入339例三类暴露的RRMM患者,接受皮下talquetamab 0.4 mg/kg每周(n=143)或0.8 mg/kg隔周(n=145)给药,既往接受T细胞重定向治疗者单独队列(n=51)接受任一方案。
主要发现
- 中位随访时间分别为每周组18.8个月、隔周组12.7个月、既往T细胞重定向治疗组14.8个月。
- 感染发生率分别为58.7%(每周组)、66.2%(隔周组)和72.5%(既往T细胞重定向治疗组),最常见为呼吸道感染包括COVID-19。
- 3/4级感染发生率分别为21.7%(每周组)、15.9%(隔周组)和27.5%(既往T细胞重定向治疗组),最常发生于第1/2周期。
- 机会性感染发生率分别为3.5%(每周组)、5.5%(隔周组)和5.9%(既往T细胞重定向治疗组)。
- 5例患者死于感染;中性粒细胞水平在第2周期恢复并维持,B细胞水平早期周期稳定、第7周期明显增加,IgG水平第3周期后恢复并至第17周期升高。
关键数值与推荐
- 感染按常见不良事件评价标准v4.03版分级,按当地指南管理。
- 开始静脉注射免疫球蛋白的患者比例分别为9.8%(每周组)、6.9%(隔周组)和5.9%(既往T细胞重定向治疗组)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Talquetamab is the first approved GPRC5D-targeting bispecific antibody for the treatment of relapsed/refractory multiple myeloma (RRMM), based on results from the phase 1/2 MonumenTAL-1 study. We report the infection profile among patients treated with talquetamab in MonumenTAL-1. Patients with triple-class exposed RRMM received subcutaneous talquetamab 0.4 mg/kg weekly or 0.8 mg/kg every other week (EOW). Patients with prior T-cell redirection therapy (TCR) were included in a separate cohort and received either schedule. Infections (graded by Common Terminology Criteria for Adverse Events v4.03) were managed per local guidelines. Patients received talquetamab (N = 339) with a median follow-up of 18.8 (weekly; n = 143), 12.7 (EOW; n = 145), and 14.8 (prior TCR; n = 51) months. Infections occurred in 58.7%, 66.2%, and 72.5% of patients, respectively; most common were respiratory infections, including COVID-19. Grade 3/4 infections occurred in 21.7% (weekly), 15.9% (EOW), and 27.5% (prior TCR) of patients, onset most common in cycles 1/2. Opportunistic infections were low (3.5%, 5.5%, and 5.9%, respectively). Five patients died due to infections. Neutrophil levels recovered at cycle 2 and were maintained throughout treatment. B-cell levels remained stable in early cycles, with notable increases at cycle 7. Immunoglobulin G levels recovered after cycle 3 and increased through cycle 17. Few patients started IV immunoglobulin following talquetamab (9.8% [weekly], 6.9% [EOW], and 5.9% [prior TCR]). Patients treated with talquetamab demonstrated relatively low rates of grade 3/4 infections and preservation of humoral immunity, distinguishing talquetamab as an important and potentially less immunosuppressive, novel treatment option for patients with RRMM. These trials were registered at www.clinicaltrials.gov as #NCT03399799 and #NCT04634552.
引用
- Schinke C, Rodriguez-Otero P, van de Donk NWCJ, et al. Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1. Blood Adv. 2025. PMID: 40864183. doi:10.1182/bloodadvances.2025016613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。